nach oben

Erschienen in:

04.10.2016 | Asthma bronchiale | Fortbildung

Rezidivierende Polyposis, CRS und Asthma

Bei charakteristischer Trias an ASS-Intoleranz-Syndrom denken

verfasst von: Prof. Dr. med. Ludger Klimek

Erschienen in: HNO Nachrichten | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zeigen Patienten die Symptome einer chronischen Rhinosinusitis, asthmatische Beschwerden und eine rasch rezidivierende Polyposis lohnt sich die Frage nach der Reaktion auf nichtsteroidale Antiphlogistika. Denn unter Umständen handelt es sich bei dem Beschwerdekomplex um ein ASS-Intoleranz-Syndrom. Klinik, Diagnostik und Therapie der Erkrankung erläutert der folgende Beitrag.

Widal F, Abrami P, Lermoyez J. Anaphylaxie et idiosyncrasie. 1992 [Anaphylaxis and idiosyncrasy. 1992]. Allergy proceedings: the official journal of regional and state allergy societies, 14(5), 373–376; discussion 371-372 (1993).CrossRef

Pfaar O, Spielhaupter M, Klimek L. Max Samter - ein Pionier und Wegbereiter der modernen Allergologie und Rhinologie. Allergo J, 8, 630–634 (2005).

Zeitz HJ. Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter's syndrome. Clinics in chest medicine, 9(4), 567–576 (1988).PubMed

Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy, 66(7), 818–829 (2011).CrossRefPubMed

Schapowal A. Pseudoallergische Reaktionen auf nicht steroidale Antiphlogistika. In: Praktische Allergologie - Schwerpunkt HNO-Heilkunde. Bachert, C (Ed. (Thieme, Stuttgart, 1998) 233–238.

Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. Bmj, 328(7437), 434 (2004).CrossRefPubMedPubMedCentral

Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear, nose, & throat journal, 86(7), 396–399 (2007).

Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J, 16(3), 432–436 (2000).CrossRefPubMed

Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy, 62(10), 1111–1118 (2007).CrossRefPubMed

10.

Szczeklik A, Sanak M. The broken balance in aspirin hypersensitivity. European journal of pharmacology, 533(1-3), 145–155 (2006).CrossRefPubMed

11.

Kirsche H, Klimek L. [ASA-intolerance syndrome and persistent rhinosinusitis: Differential diagnosis and treatment]. Hno, 63(5), 357–363 (2015).CrossRefPubMed

12.

Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 111(1), 180–186 (2003).CrossRefPubMed

13.

Fokkens W, Lund V, Mullol J. European Position Paper on R, Nasal Polyps g. European Position Paper on rhinosinusitis and nasal polyps. Rhinology. Supplement, 20, 1136 (2007).

14.

Gosepath J, Pogodsky T, Mann WJ. Characteristics of recurrent chronic rhinosinusitis after previous surgical therapy. Acta Otolaryngol, 128(7), 778–784 (2008).CrossRefPubMed

15.

Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol, 89(5), 474–478 (2002).CrossRefPubMed

16.

Caplin I, Haynes JT, Spahn J. Are nasal polyps an allergic phenomenon? Ann Allergy, 29(12), 631–634 (1971).PubMed

17.

Larsen K. The clinical relationship of nasal polyps to asthma. Allergy Asthma Proc, 17(5), 243–249 (1996).CrossRefPubMed

18.

Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol, 94(6), 652–657 (2005).CrossRefPubMed

19.

Ogino S, Harada T, Okawachi I, Irifune M, Matsunaga T, Nagano T. Aspirin-induced asthma and nasal polyps. Acta oto-laryngologica. Supplementum, 430, 21–27 (1986).

20.

Settipane GA. Nasal polyps: epidemiology, pathogenesis and treatment. Rhode Island: Oceanside Publications, (1997).

21.

Settipane GA, Chafee FH, Klein DE. Aspirin intolerance. II. A prospective study in an atopic and normal population. J Allergy Clin Immunol, 53(4), 200–204 (1974).CrossRefPubMed

22.

Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep, 9(2), 155–163 (2009).CrossRefPubMed

23.

Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol, 111(5), 913–921; quiz 922 (2003).CrossRefPubMed

24.

Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol, 98(3), 678–685 (1996).CrossRefPubMed

25.

Hillerdal G, Lindholm H. Laryngeal edema as the only symptom of hypersensitivity to salicylic acid and other substances. The Journal of laryngology and otology, 98(5), 547–548 (1984).CrossRefPubMed

26.

Baenkler HW. Intoleranz gegenüber Salicylaten/ Analgetika. Bayr Internist 5, 251–260 (2006).

27.

Buss YA, Garrelfs UC, Sticherling M. Chronic urticaria—which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. J Dtsch Dermatol Ges, 5(1), 22–29 (2007).CrossRefPubMed

28.

Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. American journal of clinical dermatology, 3(9), 599–607 (2002).CrossRefPubMed

29.

Morwood K, Gillis D, Smith W, Kette F. Aspirin-sensitive asthma. Internal medicine journal, 35(4), 240–246 (2005).CrossRefPubMed

30.

Hosemann W, Kuhnel T, Pfeifer M. [Analgesic intolerance and nasal polyps]. Laryngorhinootologie, 79(1), 53–65 (2000).PubMed

31.

Babu KS, Salvi SS. Aspirin and asthma. Chest, 118(5), 1470–1476 (2000).CrossRefPubMed

32.

Klimek L, Goebel U, Glowania A. [Management of anaphylaxis: part 2: treatment and emergency equipment]. HNO, 60(12), 1103–1113 (2012).CrossRefPubMed

33.

Dollner R, Klimek, L., Pfaar, O., Stuck, B.A., Hörmann, K. In-vitro-Testverfahren bei Analgetikaintoleranz. Allergologie, 30(7), 240–248 (2007).CrossRef

34.

Albu S, Tomescu E, Mexca Z, Nistor S, Necula S, Cozlean A. Recurrence rates in endonasal surgery for polyposis. Acta Otorhinolaryngol Belg, 58(1), 79–86 (2004).PubMed

35.

Stuck BA, Bachert C, Federspil P et al. [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery]. Hno, 55(10), 758–760, 762-754, 766-777 (2007).CrossRefPubMed

36.

Gosepath J, Mann WJ. Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ORL J Otorhinolaryngol Relat Spec, 67(3), 125–136 (2005).CrossRefPubMed

37.

Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol, 120(3), 162–166 (2011).CrossRefPubMed

38.

McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol, 20(6), 573–576 (2006).CrossRefPubMed

39.

Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol, 163(3), 1545–1551 (1999).PubMed

40.

Hissaria P, Smith W, Wormald PJ et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol, 118(1), 128–133 (2006).CrossRefPubMed

41.

Benitez P, Alobid I, de Haro J et al. A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope, 116(5), 770–775 (2006).CrossRefPubMed

42.

Karlsson G, Rundcrantz H. A randomized trial of intranasal beclomethasone dipropionate after polypectomy. Rhinology, 20(3), 144–148 (1982).PubMed

43.

Virolainen E, Puhakka H. The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology, 18(1), 9–18 (1980).PubMed

44.

Dingsor G, Kramer J, Olsholt R, Soderstrom T. Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study. Rhinology, 23(1), 49–58 (1985).PubMed

45.

Drettner B, Ebbesen A, Nilsson M. Prophylactive treatment with flunisolide after polypectomy. Rhinology, 20(3), 149–158 (1982).PubMed

46.

Bachert C, Geveart P. Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy, 54 Suppl 57, 116–123 (1999).CrossRefPubMed

47.

Stjarne P, Olsson P, Alenius M. Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg, 135(3), 296–302 (2009).CrossRefPubMed

48.

Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol, 22(1), 1–12 (2012).PubMed

49.

Klimek L, Hogger P, Pfaar O. [Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis]. Hno, 60(7), 611–617 (2012).CrossRefPubMed

50.

Shikani AH, Kourelis K, Rohayem Z, Basaraba RJ, Leid JG. Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report. Ann Otol Rhinol Laryngol, 121(11), 719–724 (2012).CrossRefPubMed

51.

Dahlen SE, Malmstrom K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med, 165(1), 9–14 (2002).CrossRefPubMed

52.

Lipworth BJ. Leukotriene-receptor antagonists. Lancet, 353(9146), 57–62 (1999).CrossRefPubMed

53.

Pauli C, Fintelmann R, Klemens C et al. [Polyposis nasi—improvement in quality of life by the influence of leukotrien receptor antagonists]. Laryngorhinootologie, 86(4), 282–286 (2007).CrossRefPubMed

54.

Yazici ZM, Sayin I, Bozkurt E, Kayhan FT. Effect of montelukast on quality of life in subjects with nasal polyposis accompanying bronchial asthma. Kulak burun bogaz ihtisas dergisi: KBB = Journal of ear, nose, and throat, 21(4), 210–214 (2011).CrossRefPubMed

55.

Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol, 98(4), 751–758 (1996).CrossRefPubMed

56.

Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol, 85(1 Pt 1), 59–65 (1990).CrossRefPubMed

57.

Schmitz-Schumann M, Schaub E, Virchow C. [Inhalation provocation test with lysine-acetylsalicylic acid in patients with analgetics-induced asthma (author's transl)]. Praxis und Klinik der Pneumologie, 36(1), 17–21 (1982).PubMed

58.

Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol, 66(1), 82–88 (1980).CrossRefPubMed

59.

Forer B, Kivity S, Sade J, Landsberg R. Aspirin desensitization for ASA triad patients—prospective study of the rhinologist's perspective. Rhinology, 49(1), 95–99 (2011).PubMed

60.

Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Current opinion in pulmonary medicine, 10(1), 51–56 (2004).CrossRefPubMed

61.

Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol, 57(5), 440–448 (1976).CrossRefPubMed

62.

Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope, 115(8), 1385–1390 (2005).CrossRefPubMed

63.

Patriarca G, Schiavino D, Nucera E, Papa G, Schinco G, Fais G. Prevention of relapse in nasal polyposis. Lancet, 337(8755), 1488 (1991).CrossRefPubMed

64.

Gosepath J, Schafer D, Mann WJ. [Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100 mg of aspirin a day]. Laryngorhinootologie, 81(10), 732–738 (2002).CrossRefPubMed

65.

McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol, 36(1), 25–30 (2013).CrossRefPubMed

66.

Pfaar O, Spielhaupter M, Wrede H. Aspirin desensitization on patients with aspirin intolerance and nasal polyps - a new therapeutic approach by the intravenous route. Allergologie, 29(8), 322–331 (2006).CrossRef

67.

Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am, 29(4), 669–675 (2009).CrossRefPubMed

68.

Pfaar O, Klimek L. Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol, 6(3), 161–166 (2006).CrossRefPubMed

69.

Umbreit C, Virchow JC, Thorn C, Hormann K, Klimek L, Pfaar O. [Aspirin-Intolerance-Syndrom: a common and interdisciplinary disease]. Internist (Berl), 51(9), 1196–1198, 1200-1191 (2010).CrossRef

70.

Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 119(1), 157–164 (2007).CrossRefPubMed

71.

Rozsasi A, Polzehl D, Deutschle T et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy, 63(9), 1228–1234 (2008).CrossRefPubMed

72.

Havel M, Ertl L, Braunschweig F et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol, 270(2), 571–578 (2013).CrossRefPubMed

73.

Comert S, Celebioglu E, Yucel T et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy, 68(11), 1443–1451 (2013).CrossRefPubMed

74.

Fruth K, Pogorzelski B, Schmidtmann I et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy, 68(5), 659–665 (2013).CrossRefPubMed

75.

Weber R, Trautmann A, Randerath W, Heppt W, Hosemann W. [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease]. Hno, 60(4), 369–383 (2012).CrossRefPubMed

76.

Rizk H. Role of aspirin desensitization in the management of chronic rhinosinusitis. Current opinion in otolaryngology & head and neck surgery, 19(3), 210–217 (2011).CrossRef

77.

Tournoij E, Peters RJ, Langenberg M, Kanhai KJ, Moll FL. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery, 37(5), 597–603 (2009).CrossRef

78.

Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol, 135(1), 245–252 (2015).CrossRefPubMed

Titel: Rezidivierende Polyposis, CRS und Asthma
Bei charakteristischer Trias an ASS-Intoleranz-Syndrom denken
verfasst von: Prof. Dr. med. Ludger Klimek
Publikationsdatum: 04.10.2016
Verlag: Springer Medizin
Schlagwörter: Asthma bronchiale
Acetylsalicylsäure
Glucocorticoide
Acetylsalicylsäure
Rhinosinusitis
Erschienen in: HNO Nachrichten / Ausgabe 5/2016
Print ISSN: 0177-1000
Elektronische ISSN: 2198-6533
DOI: https://doi.org/10.1007/s00060-016-5311-8

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bei charakteristischer Trias an ASS-Intoleranz-Syndrom denken

Zusammenfassung

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Bronchien erkennen Aprikosenduft

Schützt Daumenlutschen vor Allergien?

Asthma und COPD: Erfolgreiche Therapie ist auch eine Frage der Technik

Skepsis überwiegt

Stimme schonen und Schleimhäute befeuchten

Chronische Rhinosinusitis: Spülen ja, Dampf nein

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Update HNO